Longeveron Inc. Class A Company Profile
NASDAQ: LGVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Longeveron at a glance
Longeveron Inc. Class A (NASDAQ: LGVN) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Miami, FL. Longeveron is led by Mr. Stephen H. Willard Esq. and employs about 38 people. The company's shares have traded publicly since 2021.
At a market capitalization of $7.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001721484, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Longeveron do?
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Business description based on the company's public filings.
Company information
- Legal name
- Longeveron Inc. Class A
- Ticker
- NASDAQ: LGVN
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Stephen H. Willard Esq.
- Employees
- 38
- Headquarters
- Life Science & Technology Park, Miami, FL, United States
- Phone
- 844 470 2550
- Website
- longeveron.com
- IPO year
- 2021
- Market cap
- $7.91M
- SEC CIK
- 0001721484
Companies similar to Longeveron
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SNGXSoligenix Inc. | 0.3636 | +4.90% | $7.91M | vs LGVN |
| BOLTBolt Biotherapeutics Inc. | 4.11 | +13.22% | $7.92M | vs LGVN |
| AZTRAzitra Inc | 0.1299 | -1.59% | $7.87M | vs LGVN |
| FBLGFibroBiologics Inc. | 1.13 | +1.80% | $7.86M | vs LGVN |
| CNSPCNS Pharmaceuticals Inc. | 5.35 | 0.00% | $7.82M | vs LGVN |
| APREAprea Therapeutics Inc. | 0.6044 | +8.28% | $7.61M | vs LGVN |
| APUSApimeds Pharmaceuticals US Inc. | 5.02 | -8.89% | $7.58M | vs LGVN |
| CURXCuranex Pharmaceuticals Inc | 5.31 | +11.55% | $8.33M | vs LGVN |